Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 4/20 | 0.33 |
| ▸ | MMP2 | P08253 | 3/20 | 0.33 |
| ▸ | MMP8 | P22894 | 3/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 5/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122184 | 0.81 | KDM4E (0.33) | KDM4ETDP1CTSAACHE | |
| SCHEMBL22540462 | 0.74 | TDP1 (0.37) | KDM4ETDP1CTSAACHEALDH1A1 | |
| SCHEMBL17346874 | 0.73 | — | — | |
| SCHEMBL15867910 | 0.73 | — | — | |
| SCHEMBL25894071 | 0.72 | CTSA (0.33) | KDM4ETDP1CTSAACHEMMP1 | |
| SCHEMBL18736413 | 0.71 | FDPS (0.43) | TDP1MMP1MMP2MMP8MMP3 | |
| SCHEMBL24418960 | 0.71 | — | — | |
| SCHEMBL11882370 | 0.71 | — | — | |
| SCHEMBL20078943 | 0.71 | KDM4E (0.44) | KDM4ETDP1CTSAACHEMMP1 | |
| SCHEMBL24540277 | 0.71 | CTSA (0.36) | KDM4ECTSAACHEALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-04-13 | — | — | US | disclosed |
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | KDM4E 2595/4885TDP1 4781/4885CTSA 2046/4885 |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | KDM4E 4511/4885TDP1 3249/4885CTSA 1275/4885 |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | KDM4E 2595/4885TDP1 4781/4885CTSA 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.